01 — At A Glance
They Admit It. They Destroyed Revenue On Purpose.
- 52-Week High / Low₹409 / ₹268
- Q3 FY26 Revenue₹231 Cr
- Q3 FY26 PAT₹12.4 Cr
- Q3 EPS₹1.24
- Full-Year FY25 EPS₹6.95
- Book Value₹62.9
- Price to Book4.68x
- Dividend Yield0.03%
- Debt / Equity0.58x
- ROCE13.2%
The Admission Nobody Wanted: In Q3 FY26, Gufic’s management explicitly told investors they sacrificed ₹14–16 crore of revenue to fix working-capital chaos. PAT crashed 36% YoY as a result. But here’s the plot twist: management said this during the earnings call on February 16, 2026 — AFTER the Q3 results were published and the stock had already crashed 16% in 3 months. Translation: bad communication mixed with worse execution.
02 — Introduction
When Your Pharma Shop Gets Too Successful For Hospital Billing
Gufic BioSciences is a mid-sized pharmaceutical company that manufactures injectables, APIs (bulk drugs), botulinum toxin for aesthetics, and contract manufacturing for other pharma companies. It’s been around since the 1960s—five decades of boring, reliable manufacturing. Until December 2024, when they opened a ₹300+ crore Indore manufacturing plant and suddenly things got complicated.
The company makes products that hospitals actually buy repeatedly: sepsis treatments, resistant infection antibiotics, fertility hormones, and now (beginning 2026) a botulinum toxin business with 23% market share and a freshly-signed Canadian fillers licensing deal. Repeat customers. Long qualification cycles. The boring foundation that actually makes money — except when it doesn’t.
In Q3 (October-December 2025), management did something unusual: it admitted that it had deliberately switched from direct-to-hospital billing (good for reported revenue, terrible for cash collection) back to distributor/stockist billing (slower revenue reported, faster cash in). This caused a ₹14–16 crore revenue “hit” that management only explained to investors during the February 2026 earnings call. By then, the stock had already tanked. The lesson: admit your mistakes, but admit them BEFORE quarterly results, not after.
From The Feb 16 Concall: CFO: “We are revamping our operations from going from direct hospital supply to taking it back as a stockist because a lot of our working capital was getting affected in the long cycle.” CEO added: “I don’t want to have one more year where I submit something and I don’t deliver.” Translation: Panic mixed with occasional competence.
03 — Business Model: The Injection, Toxin, And Bulk Drug Tango
Four Businesses. One Balance Sheet. All Of Them Complicated.
Gufic operates four distinct but interconnected business lines. First: Domestic Branded (~60% of revenue) — hospital injectables (liquid and lyophilized), critical care products (sepsis, resistant infections), women’s health (fertility), and nutraceuticals. This is the crown jewel because hospitals have money and they eventually pay. Second: CMO (Contract Manufacturing for 70+ companies including Serum Institute, Biocon, Lupin, Cipla) — ~20–25% of revenue, pure cash generation, repeat customers, zero distribution complexity.
Third: International Business (~12% of revenue, growing fast) — exports to 15+ countries with 130+ registered products. Management cited ₹120 crore export base with 40% growth already. If Indore gets USFDA approval, export revenue could 2x within 18 months. Fourth: Bulk Drugs (APIs) — manufactured for internal use and external sale, volume-based, margin-sensitive, largely invisible to investors.
The problem: all four lines have different cycles, margins, and working-capital needs. Injectables = high margin, high working capital. CMO = stable, low working capital. Exports = regulatory gated, high margin once approved. APIs = competitive, volume-focused. Managing all four while ramping a new ₹300 crore plant is like juggling while riding a motorcycle.
Injectables80%Of Revenue
India Exposure89%Domestic Heavy
Doctor Network120K+Prescriber Reach
Botox Market Share23%India IQVIA
The Indore Gamble (From Concall): Management stated: “Navsari is chock-a-block and saturated.” So they spent ₹300+ crores building Indore. Current output ₹36–38 cr/quarter; target ₹40–42 cr. Headcount grew from 350 to 480–500. But utilization is only ~50%, meaning fixed costs are brutal. CFO: “Indore will achieve EBITDA breakeven only in Q4 FY26, and broader fixed-cost absorption through FY27.” Translation: This plant is a 2-year albatross before it becomes profitable.
💬 If you were a hospital procurement officer, would you risk switching from Baxter to an Indian injection brand? What if the price difference was 15%? 25%? Comment your risk-tolerance threshold below.
04 — Financials Overview
Q3 FY26: The Numbers (And The Excuses)
Result type: QUARTERLY RESULTS | Q3 EPS: ₹1.24 | Q1 EPS: ₹1.30, Q2 EPS: ₹1.68 | Annualised EPS (Avg Q1/Q2/Q3 × 4): ₹5.63
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 231 | 208 | 224 | +11.1% | +3.1% |
| EBITDA | 37.1 | 34.0 | 37.9 | +9.1% | -2.1% |
| EBITDA Margin % | 16.0% | 16.3% | 16.5% | -30 bps | -50 bps |
| PAT | 12.4 | 19.0 | 14.9 | -34.7% | -16.8% |
| EPS (₹) | 1.24 | 1.93 | 1.49 | -35.8% | -16.8% |
Decoding The Collapse (Management’s Own Words): Revenue grew only 11% YoY, but management cited a deliberate ₹14–16 crore sacrifice in Q3 for working-capital reset. Without that, organic growth would be ~22% YoY. PAT fell 35% due to: (1) Fixed costs at Indore (~₹8–10 cr/quarter); (2) Interest costs (~₹8–10 cr/quarter); (3) Depreciation (~₹8 cr/quarter). Management’s guidance for FY27: “Minimum 15% revenue growth.” Translation: Even the CEO is nervous about the numbers and wants to set low expectations.
05 — Valuation: Trading At 59x On A 13% ROCE Company
The Math That Makes Auditors Squint
